Format

Send to

Choose Destination
Biomark Res. 2014 Sep 8;2:16. doi: 10.1186/2050-7771-2-16. eCollection 2014.

Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphoma.

Author information

1
Yale Cancer Center, PO Box 208028, 333 Cedar Street, TMP 3, New Haven, CT 06520-8028, USA.
2
Hospices Civils de Lyon, Lyon, France.
3
Memorial Sloan Kettering Cancer Center, New York, NY, USA.
4
Thomas Jefferson University, Philadelphia, PA, USA.
5
Peter MacCallum Cancer Centre and University of Melbourne, East Melbourne, Victoria, Australia.
6
Moffitt Cancer Center, Tampa, FL, USA.
7
Royal North Shore Hospital, Sydney, New South Wales, Australia.
8
Boston Medical Center, Boston, MA, USA.
9
Hospital Universitario de Salamanca, Salamanca, Spain.
10
Wroclaw Medical University, Wroclaw, Poland.
11
University of Pennsylvania, Philadelphia, PA, USA.
12
J Nichols LLC, Swampscott, MA, USA.
13
Veristat, LLC, Holliston, MA, USA.
14
Guy's and St Thomas' Hospital, London, England, United Kingdom.

Abstract

BACKGROUND:

Histone deacetylase inhibitor romidepsin has demonstrated durable clinical responses and tolerability in patients with relapsed/refractory peripheral and cutaneous T-cell lymphoma (PTCL, CTCL). Selection of novel drug therapies for patients with relapsed/refractory aggressive lymphoma requires not only considerations regarding efficacy but also careful evaluation of toxicities as well as overall clinical benefit. The purpose of this analysis was to examine common adverse events (AEs) reported in pivotal trials of romidepsin in relapsed/refractory PTCL or CTCL and to more clearly define the overall AE profile in these populations.

METHODS:

Patients with relapsed/refractory PTCL or CTCL were treated with romidepsin at 14 mg/m(2) as a 4-hour intravenous infusion on days 1, 8, and 15 of 28-day cycles for up to 6 cycles; patients with at least stable disease could extend therapy until progressive disease or another withdrawal criterion was met. All enrolled patients who received ≥ 1 dose of romidepsin were included in the AE analyses.

RESULTS:

Overall, safety profiles of common AEs were similar, although patients with relapsed/refractory PTCL had more frequent hematologic toxicities and grade ≥ 3 infections. In both patient populations, the greatest incidence of grade ≥ 3 AEs and the majority of discontinuations due to AEs occurred during cycles 1-2. Early discontinuations were primarily related to infection, thrombocytopenia, or electrocardiogram abnormalities, confirming the need to closely monitor patients with poor bone marrow reserve or other comorbidities. Despite this, 28% of patients with relapsed/refractory PTCL and 36% of patients with relapsed/refractory CTCL continued on romidepsin treatment for ≥ 6 cycles.

CONCLUSIONS:

This study demonstrates that patients with relapsed/refractory PTCL or CTCL have similar AE profiles with romidepsin treatment, although patients with PTCL experienced more frequent and more severe hematologic toxicities and more frequent grade ≥ 3 infections. The greatest incidence of grade ≥ 3 AEs and the majority of discontinuations due to AEs occurred during treatment cycles 1-2. Extended dosing of romidepsin can be tolerated in responding patients.

TRIAL REGISTRATION:

NCT00426764,NCT00106431.

KEYWORDS:

Adverse events; CTCL; Discontinuations; PTCL; Romidepsin

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center